Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Massimo Martino, Francesco Lanza, Taner Demirer, Tiziana Moscato, Simona Secondino, Paolo Pedrazzoli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Erythropoiesis-stimulating agents (ESAs) are used in treating cancer-and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.Areas covered: A systematic review has been conducted to examine the current evidence for the efficacy and safety of using ESAs in hematopoietic stem cell transplants (HSCTs).Expert opinion: Despite the international recommendations for the use of ESAs in treating different malignancies, there is a lack of guidelines for their use in patients undergoing HSCT. An evaluation of published clinical trials shows that there are no available powerful studies concerning the use of ESAs in this setting, with only heterogeneous and small numbers of patients reported so far. Nevertheless, the more robust and intriguing of these data suggest that the ESA's administration at an appropriate time after the infusion of stem cells may be effective both in autologous and allogeneic HSCTs. New guidelines are required, overseen by an expert in the in the field of stem cell transplantation.

Original languageEnglish
Pages (from-to)195-211
Number of pages17
JournalExpert Opinion on Biological Therapy
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Hematinics
Hematopoietic Stem Cell Transplantation
Stem cells
Hematopoietic Stem Cells
Transplants
Guidelines
Blood
Erythrocyte Transfusion
Expert Testimony
Stem Cell Transplantation
Chemotherapy
Anemia
Neoplasms
Stem Cells
Erythrocytes
Quality of Life
Clinical Trials
Safety
Drug Therapy
Cells

Keywords

  • Allogeneic hematopoietic stem cell transplant
  • Autologous hematopoietic stem cell transplant
  • Erythropoiesis-stimulating agents
  • Erythropoietin

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Cite this

Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation. / Martino, Massimo; Lanza, Francesco; Demirer, Taner; Moscato, Tiziana; Secondino, Simona; Pedrazzoli, Paolo.

In: Expert Opinion on Biological Therapy, Vol. 15, No. 2, 01.02.2015, p. 195-211.

Research output: Contribution to journalArticle

@article{760ac1206c184b6893eaa7d2c98d893e,
title = "Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation",
abstract = "Introduction: Erythropoiesis-stimulating agents (ESAs) are used in treating cancer-and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.Areas covered: A systematic review has been conducted to examine the current evidence for the efficacy and safety of using ESAs in hematopoietic stem cell transplants (HSCTs).Expert opinion: Despite the international recommendations for the use of ESAs in treating different malignancies, there is a lack of guidelines for their use in patients undergoing HSCT. An evaluation of published clinical trials shows that there are no available powerful studies concerning the use of ESAs in this setting, with only heterogeneous and small numbers of patients reported so far. Nevertheless, the more robust and intriguing of these data suggest that the ESA's administration at an appropriate time after the infusion of stem cells may be effective both in autologous and allogeneic HSCTs. New guidelines are required, overseen by an expert in the in the field of stem cell transplantation.",
keywords = "Allogeneic hematopoietic stem cell transplant, Autologous hematopoietic stem cell transplant, Erythropoiesis-stimulating agents, Erythropoietin",
author = "Massimo Martino and Francesco Lanza and Taner Demirer and Tiziana Moscato and Simona Secondino and Paolo Pedrazzoli",
year = "2015",
month = "2",
day = "1",
doi = "10.1517/14712598.2015.971749",
language = "English",
volume = "15",
pages = "195--211",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

AU - Martino, Massimo

AU - Lanza, Francesco

AU - Demirer, Taner

AU - Moscato, Tiziana

AU - Secondino, Simona

AU - Pedrazzoli, Paolo

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Introduction: Erythropoiesis-stimulating agents (ESAs) are used in treating cancer-and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.Areas covered: A systematic review has been conducted to examine the current evidence for the efficacy and safety of using ESAs in hematopoietic stem cell transplants (HSCTs).Expert opinion: Despite the international recommendations for the use of ESAs in treating different malignancies, there is a lack of guidelines for their use in patients undergoing HSCT. An evaluation of published clinical trials shows that there are no available powerful studies concerning the use of ESAs in this setting, with only heterogeneous and small numbers of patients reported so far. Nevertheless, the more robust and intriguing of these data suggest that the ESA's administration at an appropriate time after the infusion of stem cells may be effective both in autologous and allogeneic HSCTs. New guidelines are required, overseen by an expert in the in the field of stem cell transplantation.

AB - Introduction: Erythropoiesis-stimulating agents (ESAs) are used in treating cancer-and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.Areas covered: A systematic review has been conducted to examine the current evidence for the efficacy and safety of using ESAs in hematopoietic stem cell transplants (HSCTs).Expert opinion: Despite the international recommendations for the use of ESAs in treating different malignancies, there is a lack of guidelines for their use in patients undergoing HSCT. An evaluation of published clinical trials shows that there are no available powerful studies concerning the use of ESAs in this setting, with only heterogeneous and small numbers of patients reported so far. Nevertheless, the more robust and intriguing of these data suggest that the ESA's administration at an appropriate time after the infusion of stem cells may be effective both in autologous and allogeneic HSCTs. New guidelines are required, overseen by an expert in the in the field of stem cell transplantation.

KW - Allogeneic hematopoietic stem cell transplant

KW - Autologous hematopoietic stem cell transplant

KW - Erythropoiesis-stimulating agents

KW - Erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=84920941654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920941654&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.971749

DO - 10.1517/14712598.2015.971749

M3 - Article

C2 - 25315815

AN - SCOPUS:84920941654

VL - 15

SP - 195

EP - 211

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -